Nuzenio

Gurufocus Bmy Looks

Gurufocus Bmy Looks entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 15 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Timeline

Sat, 08 Aug 2026 21:26:11 GMTBMY Looks 14.7% Overvalued on GF Value™ as Dividend Sustainabili - GuruFocus
Wed, 05 Aug 2026 21:35:11 GMTBristol-Myers Squibb Co (BMY) Stock Down 3.4% but Still Overvalued -- GF Score: 71/100 - GuruFocus
Wed, 05 Aug 2026 16:03:40 GMTBMY Upgraded by Argus Research -- Rating Changed to Buy - GuruFocus
Wed, 05 Aug 2026 15:02:10 GMTBMY Looks 17.0% Overvalued on GF Value™ as Dividend Sustainabili - GuruFocus
Tue, 04 Aug 2026 10:52:30 GMTBMY Maintained by Citigroup -- Price Target Raised to $70 - GuruFocus
Mon, 03 Aug 2026 18:00:00 GMTPotential Merger Between Bristol-Myers Squibb (BMY) and AstraZen - GuruFocus

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Gurufocus Bmy Looks.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.